Company News
-
LifeTech Scientific Corporation Announced 2024 Annual Results：Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%LifeTech Scientific Corporation, a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiariesannounced the audited consolidated results for the year ended 31 December 2024.2025 / 03 / 28
-
LifeTech Scientific Corporation Announced 2023 Annual Results：International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid DevelopmentLifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries announced the audited consolidated results for the year ended 31 December 2023.2024 / 04 / 02
-
LifeTech Scientific Corporation Announced 2024 Interim Results：International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the “Group”) announced the consolidated results for the six months ended 30 June 2024 (the “Reporting Period”).2024 / 08 / 30
-
LifeTech Scientific Corporation（1302.HK） Announces 2023 Interim ResultsLifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced the unaudited consolidated results of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2023 (the “Reporting Period”).2023 / 08 / 30
-
LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results.2023 / 03 / 30
-
FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the USLifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States2022 / 09 / 05
-
LifeTech Scientific Corporation（1302.HK）Announces 2022 Interim ResultsRevenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items2022 / 08 / 31
-
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual ResultsLifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 annual results.2022 / 03 / 30
-
LifeTech and Medtronic Further Strategic Collaboration to Open New Chapter of Domestically-Made MRI-Conditional PacemakersLifeTech Scientific Corporation (LifeTech, 01302.HK) announced that it has extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone™ domestic pacemaker project" and to start the collaboration on domestically-made MRI-conditional pacemakers. Together with MRI-conditional leads, these products will address growing MRI-related therapeutic needs in China.2021 / 12 / 16
-
LifeTech Scientific Corporation Announces 2021 Interim ResultsLifeTech Scientific Corporation (LifeTech, 01302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 interim results.2021 / 08 / 30
